The product, given its focus on relieving head pain, doesnâ€™t generally have the opportunity to "speak on a larger scale," especially during a presidential election, said Scott Yacovino, a senior brand manager for Excedrin and the United States pain business at GlaxoSmithKline. This situation was a "perfect storm," he said. " Even during the first debate, there was a lot of organic chatter around people getting headaches and the election causing headaches," Mr. Yacovino said. 